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Abstract: 
Pancreatic cancer is the fourth leading cause of cancer related deaths in the United 
States due to its severe aggressiveness and lethal malignancy. Epidermal Growth 
Factor Receptor (EGFR) is over expressed in more than 95% of human pancreatic 
cancer patients.  A number of peptides and monoclonal antibodies have been 
developed to target the EGFR in pancreatic cancer.  Our research has focused on 
developing EGFR targeting biomolecule conjugated gold nanoparticles for the diagnosis 
and staging of various cancers. In this study, we synthesized a series of Antibody EGFR 
and EGFR-peptide conjugated AuNPs.  We investigated the in vivo EGFR targeting 
characteristics of these conjugates in pancreatic tumor bearing SCID mice models.  Our 
investigation establishes that the peptide conjugated AuNPs have high in vivo mobility 
and targets pancreatic tumor effectively. We have also established that EGFR-peptide –
AuNP conjugates act as better X-ray contrast agents for early detection of pancreatic 
cancer in mice models.  The details of this comparative study will be presented in this 
poster. 
 
